相关实验视频

Updated: Jul 11, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

降低糖尿病中的脂质:最新情况

Alan Chait¹, Robert H Eckel², Michal Vrablik³

¹Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, WA, USA.

Atherosclerosis

|November 9, 2023

概括

糖尿病患者经历了加速动脉样性心血管疾病 (ASCVD). 组合疗法,如他类药物加以西西米布,被推用于管理失脂症和预防ASCVD事件.

科学领域:

心脏病学心脏病学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

糖尿病加速动脉样硬化心血管疾病 (ASCVD) 通过诸如失脂症,高血糖症,氧化应激和炎症等机制.
1型糖尿病具有独特的因素,有助于加速动脉样硬化.
有临床指导方针用于查,风险评估和糖尿病患者ASCVD的治疗.

研究的目的:

审查目前在糖尿病患者中预防ASCVD的战略.
讨论脂质管理在减轻ASCVD风险中的作用.
评估各种治疗干预措施的有效性和理由.

主要方法:

审查现有的临床指导方针和治疗方法,以预防ASCVD糖尿病.
对他类药物治疗的益处和对补充治疗的需要的分析.
评估针对脂蛋白代谢的新兴疗法.

主要成果:

类固醇药物治疗显著减少糖尿病患者心血管疾病 (CVD) 的发生.
许多患者需要额外的治疗方法 (ezetimibe,bempedoic acid,PCSK9抑制剂) 来实现推的低密度脂蛋白 (LDL) 目标.
组合疗法,特别是他类药物加以替,是一种合理的初始治疗策略.
伊可萨乙烯显示有好处,可能是通过非甘油三降低机制.
像ApoC-III和ANGPTL3抑制剂这样的新药显示出进一步降低脂蛋白的前景.

结论:

积极的脂质管理对于预防糖尿病中ASCVD至关重要.
为了达到LDL目标,通常需要组合疗法.
新兴的治疗方法在未来有可能在这个人群中提高ASCVD风险降低.

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...